ArticleFrontiers in endocrinology2026
Diabetic retinopathy severity is associated with renal function deterioration in patients with diabetic kidney disease: a retrospective cohort study.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To investigate whether the severity of diabetic retinopathy (DR) and the presence of hard exudates (HEs) are associated with renal function deterioration in patients with diabetic kidney disease (DKD). Methods: This is a retrospective cohort study including 140 patients with DKD. The outcome was the progression of DKD (an estimated glomerular filtration (eGFR) decline (%)>15%) over a 5-year follow-up period. A total of 101 patients had eGFR parameters during the follow-up. DR was categorized into nonproliferative DR (NPDR) and proliferative DR (PDR). HEs were identified via optical coherence tomography (OCT). Clinical and laboratory data were acquired from medical records. The influence of the severity of DR and the presence of HEs were assessed via Cox regression. Results: The mean follow-up time was 34.31 (± 16.36) months. A significant difference was found in eGFR decline (%) (P = 0.024) between the absent DR, NPDR and PDR groups. eGFR decline (%) was more severe in patients with HEs than in those without HEs (P = 0.011). After adjustment for age, body mass index (BMI), glycosylated hemoglobin (HbA1c), low-density lipoprotein cholesterol (LDL-C), systolic blood pressure, eGFR at baseline, urine albumin creatine ratio (UACR) stage at baseline, use of Sodium-Glucose Linked Transporter 2 (SGLT2) inhibitors, as well as potential confounders such as duration of Diabetic mellitus (DM), use of Renin-Angiotensin System Inhibitors (RAS) inhibitors and Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs), Cox regression revealed that PDR (p=0.035) and NPDR (p=0.049) were independently associated with renal function deterioration. Compared with the participants in the absent DR group, participants with PDR, as well as NPDR presented a nearly threefold greater risk (adjusted HR = 2.88; 95% CI: 1.08-7.71; adjusted HR = 2.78; 95% CI: 1.004-7.70, respectively). However, the presence of HEs was not independently associated with renal function deterioration in the adjusted Cox model (P = 0.567). Conclusions: DR severity was independently associated with the progression of DKD, whereas HEs were not. DKD patients with PDR as well as NPDR should undergo kidney function testing more frequently and receive early intervention to prevent renal function deterioration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.